Skip to main content

Advertisement

Table 1 The clinical trials of next generation of CAR-T cells in cancer immunotherapy

From: Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

Safety strategy Target Identifier Disease Treatment arms Phase Stage Sponsor Comments
EGFRt + cetuximab CD19 NCT02028455 CD19+ acute leukemia Anti-CD19 CAR-T/EGFRt I/II Recruiting Seattle Children’s Hospital To study the MTD and efficacy of CAR-T cells
NCT02146924 High-risk ALL Anti-CD19 CAR-T/EGFRt I Recruiting City of Hope Medical Center To study the side effects and best dose of CAR-T cells
NCT01815749 Recurrent or high-risk NHL Anti-CD19 CAR-T/EGFRt +auto-HSCT I Active, not recruiting City of Hope Medical Center To study the side effects and best dose of CAR-T cells
NCT03579888 CD19+ lymphoid malignancies Anti-CD19 CAR-T/EGFRt +Cyclophosphamide +Fludarabine I Not yet recruiting M.D. Anderson Cancer Center To study the side effects and best dose of CAR-T cells
NCT02051257 Recurrent B-cell NHL Anti-CD19 CAR-T/EGFRt I Active, not recruiting City of Hope Medical Center To study the highest dose of memory enriched T cells
NCT01865617 R/R CLL, NHL or ALL Anti-CD19 CAR-T/EGFRt I/II Recruiting Fred Hutchinson Cancer Research Center To study the side effects and best dose of CAR-T cells
NCT03103971 R/R B-Cell NHL or ALL Anti-CD19 CAR-T/EGFRt +Cyclophosphamide +Fludarabine I Recruiting Fred Hutchinson Cancer Research Center To study the side effects of CAR-T cells
NCT03085173 R/R CLL Anti-CD19 CAR-T/EGFRt I Recruiting Memorial Sloan Kettering Cancer Center To study the MTD of CAR-T cells
CD123 NCT02159495 CD123+ R/R AML and persistent/recurrent BPDCN Anti-CD123 CAR-T/EGFRt +Fludarabine I Recruiting City of Hope Medical Center To study the side effects and the best dose of CAR-T cells
NCT03114670 Recurrent AML after allo-HSCT Anti-CD123 CAR-T/EGFRt I Recruiting Affiliated Hospital to Academy of Military Medical Sciences To study the safety and effectiveness of CAR-T cells
CD22 NCT03244306 CD22+ leukemia Anti-CD22 CAR-T/EGFRt I Active, not recruiting Seattle Children’s Hospital To study the safety and feasibility of CAR-T cells
CD171 NCT02311621 Neuroblastoma Anti-CD171 CAR-T/EGFRt I Recruiting Seattle Children’s Hospital To study the MTD of CAR-T cells
EGFR NCT03618381 R/R solid tumors Anti-EGFR CAR-T/EGFRt I Recruiting Seattle Children’s Hospital To study the safety, feasibility, and efficacy of CAR-T cells
HER2 NCT03500991 HER2+ R/R pediatric CNS tumors Anti-HER2 CAR-T/EGFRt I Recruiting Seattle Children’s Hospital To study the safety and feasibility of CAR-T cells via an indwelling CNS catheter
BCMA NCT03070327 Multiple myeloma Anti-BCMA CAR-T/EGFRt +Cyclophosphamide +Lenalidomide I Recruiting Memorial Sloan Kettering Cancer Center To study the safety of CAR-T cells
iCasp9+ AP1903 GD2 NCT01822652 Neuroblastoma Anti-GD2 CAR-T/iCasp9 I Active, not recruiting Baylor College of Medicine To study the highest dose of CAR-T cells
NCT01953900 GD2+ osteosarcoma neuroblastoma Anti-GD2 CAR-T/iCasp9 I Recruiting Baylor College of Medicine To study the largest safe dose of CAR-T cells
NCT02107963 GD2+ solid tumors Anti-GD2 CAR-T/iCasp9 +Cyclophosphamide I Completed National Cancer Institute No results posted
NCT03721068 Neuroblastoma Anti-GD2 CAR-T/IL-15/iCasp9 + Fludarabine +Cyclophosphamide I Recruiting UNC Lineberger Comprehensive Cancer Center To study the safety and feasibility of CAR-T cells
CD19 NCT03016377 R/R ALL Anti-CD19 CAR-T/iCasp9 +Cyclophosphamide +Fludarabine I Recruiting UNC Lineberger Comprehensive Cancer Center To study the safety and feasibility of CAR-T cells, and the optimal dose of AP1903
NCT03696784 R/R B-cell lymphoma Anti-CD19 CAR-T/iCasp9 + Bendamustine +Fludarabine I Not yet recruiting UNC Lineberger Comprehensive Cancer Center To study the safety and feasibility of CAR-T cells
CD19 CD22 NCT03098355 B-cell leukemia and lymphoma Anti-CD19/22 CAR-T/iCasp9 + IL-2 I/II Recruiting Zhujiang Hospital To study the safety, efficacy and persistence of CAR-T cells
CD30 NCT02274584 CD30+ lymphomas Anti-CD30 CAR-T/iCasp9 I/II Recruiting Peking University To study the safety of CAR-T cells
Mesothelin NCT02414269 Mesothelioma, lung cancer or breast cancer Anti-mesothelin CAR-T/iCasp9 + Cyclophosphamide I Recruiting Memorial Sloan Kettering Cancer Center To study the safety of CAR-T cells
TanCAR CD19 CD20 NCT03019055 R/R CD19+ or CD20+ B-cell malignancies Anti-CD19/20 CAR-T cells I/II Recruiting Medical College of Wisconsin To study the safety and feasibility of CAR-T cells
NCT03097770 R/R B-cell leukemias and lymphomas Anti-CD19/20-CAR-T cells NA Recruiting Chinese PLA General Hospital To study the safety and feasibility, and the duration of in vivo survival of tanCART-19/20 cells
  1. EGFRt: truncated epidermal growth factor receptor; MTD: maximum tolerated dose; CNS: central nervous system; AML: acute myeloid leukemia; BPDCN: blastic plasmacytoid dendritic cell neoplasm; Allo-HSCT: allogeneic hematopoietic stem cell transplantation; Auto-HSCT: autologous hematopoietic stem cell transplantation; ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin’s lymphoma; CLL: chronic lymphoblastic leukemia; R/R: relapsed/refractory; NA: not applicable